These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 34741169)

  • 1. Immune cell-mediated features of non-alcoholic steatohepatitis.
    Huby T; Gautier EL
    Nat Rev Immunol; 2022 Jul; 22(7):429-443. PubMed ID: 34741169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Fukusato T
    World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crucial role of T cells in NAFLD-related disease: A review and prospect.
    Mao T; Yang R; Luo Y; He K
    Front Endocrinol (Lausanne); 2022; 13():1051076. PubMed ID: 36457551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
    Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
    Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endoplasmic reticulum stress in innate immune cells - a significant contribution to non-alcoholic fatty liver disease.
    Zhou L; Shen H; Li X; Wang H
    Front Immunol; 2022; 13():951406. PubMed ID: 35958574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-Cell Data Analysis Reveals Critical Hepatic Cells Subpopulations in the Progression of Non-alcoholic Fatty Liver Disease to Non-Alcoholic Steatohepatitis.
    Zhao C; Ji G; Zhao X; Ma T; Li Y; Wu W; Zhou L
    Comb Chem High Throughput Screen; 2024 May; ():. PubMed ID: 38803181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of immune cells in metabolism-related liver inflammation and development of non-alcoholic steatohepatitis (NASH).
    Nati M; Haddad D; Birkenfeld AL; Koch CA; Chavakis T; Chatzigeorgiou A
    Rev Endocr Metab Disord; 2016 Mar; 17(1):29-39. PubMed ID: 26847547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis.
    Bellanti F; Villani R; Facciorusso A; Vendemiale G; Serviddio G
    Free Radic Biol Med; 2017 Oct; 111():173-185. PubMed ID: 28109892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promising therapies for treatment of nonalcoholic steatohepatitis.
    Noureddin M; Zhang A; Loomba R
    Expert Opin Emerg Drugs; 2016 Sep; 21(3):343-57. PubMed ID: 27501374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging Roles of T Cells in the Pathogenesis of Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.
    Hirsova P; Bamidele AO; Wang H; Povero D; Revelo XS
    Front Endocrinol (Lausanne); 2021; 12():760860. PubMed ID: 34777255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
    Dhamija E; Paul SB; Kedia S
    Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
    J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD44 is a key player in non-alcoholic steatohepatitis.
    Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
    J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histopathological Diagnosis of Nonalcoholic Steatohepatitis (NASH).
    Giashuddin S; Alawad M
    Methods Mol Biol; 2022; 2455():1-18. PubMed ID: 35212981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits.
    Peiseler M; Schwabe R; Hampe J; Kubes P; Heikenwälder M; Tacke F
    J Hepatol; 2022 Oct; 77(4):1136-1160. PubMed ID: 35750137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are oxidative stress mechanisms the common denominator in the progression from hepatic steatosis towards non-alcoholic steatohepatitis (NASH)?
    Tariq Z; Green CJ; Hodson L
    Liver Int; 2014 Aug; 34(7):e180-90. PubMed ID: 24621397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of IFN in the development of NAFLD and NASH.
    Møhlenberg M; Terczynska-Dyla E; Thomsen KL; George J; Eslam M; Grønbæk H; Hartmann R
    Cytokine; 2019 Dec; 124():154519. PubMed ID: 30139548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice.
    Xu B; Jiang M; Chu Y; Wang W; Chen D; Li X; Zhang Z; Zhang D; Fan D; Nie Y; Shao F; Wu K; Liang J
    J Hepatol; 2018 Apr; 68(4):773-782. PubMed ID: 29273476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical and molecular-genetic indicators of inflammation and apoptosis in liver cirrhosis as an outcome of the progression of non-alcoholic steatohepatitis.
    Kurbatova IV; Topchieva LV; Dudanova OP; Shipovskaya AA
    Ter Arkh; 2019 May; 91(4):21-27. PubMed ID: 31094472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Animal Models of Non-alcoholic Fatty Liver Diseases and Its Associated Liver Cancer.
    Lau JKC; Zhang X; Yu J
    Adv Exp Med Biol; 2018; 1061():139-147. PubMed ID: 29956212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.